华东医药：与威凯尔就VC005的商业化合作生效，将支付首付款5000万元

Group 1 - The core point of the news is that East China Pharmaceutical has signed an exclusive commercialization agreement for the oral formulation VC005 with Jiangsu Weikail Pharmaceutical Technology Co., Ltd, which is now effective [1] - East China Pharmaceutical (Hangzhou) has obtained exclusive commercialization rights for VC005 in mainland China, with an initial payment of 50 million RMB and potential milestone payments up to 180 million RMB [1] - Jiangsu Weikail has a pipeline of innovative drugs with multiple clinical projects in various stages, covering indications such as cardiovascular, oncology, autoimmune, and inflammatory diseases [1] Group 2 - VC005 is a novel, potent, and selective second-generation oral JAK1 inhibitor, developed for treating inflammatory and autoimmune diseases, with ongoing clinical development for conditions like moderate to severe atopic dermatitis and ankylosing spondylitis [2] - The clinical efficacy of VC005 in moderate to severe atopic dermatitis has shown comparable results to Upadacitinib, with rapid relief of itching observed on the day of administration [2] - VC005 is also in various stages of clinical trials for other indications, including ankylosing spondylitis and rheumatoid arthritis, with a sustained-release formulation under development [2]